Novartis Finalizes US Expansion with Seventh Facility to Strengthen End-to-End Drug Manufacturing

Novartis has completed a significant milestone in its US expansion strategy with the addition of a seventh new facility in Morrisville, North Carolina. The site will focus on manufacturing active pharmaceutical ingredients (APIs) for oral solid dosage forms and RNA-based therapies, reflecting the company’s push into next-generation therapeutic modalities.The facility is designed to strengthen end-to-end production capabilities within the United States, enabling Novartis to support the full lifecycle of drug manufacturing domestically—from API production through final finished dosage forms. According to the company, this marks a first in its ability to integrate multiple advanced technology platforms within a single regional manufacturing network.

The expansion is part of a broader commitment that includes 10 total facilities across manufacturing and R&D, seven of which are newly built. Collectively, these sites are intended to modernize and scale Novartis’ production footprint while improving flexibility across different therapeutic classes.

In November 2025, Novartis announced the construction of a new site in Durham, NC, including two new facilities for biologics production, along with sterile packaging. The company also announced intentions of growing its current Durham plant centering on gene therapy production to include the sterile filling of biologics into syringes and vials.

Why is Novartis investing heavily in US-based manufacturing?

The expansion is part of a $23 billion, multi-year investment strategy aimed at strengthening supply chain resilience and ensuring uninterrupted access to medicines for US patients. The pharmaceutical industry has increasingly shifted toward domestic manufacturing in response to global supply disruptions exposed during recent years, as well as geopolitical uncertainties affecting global logistics networks.

For Novartis, the investment is also about long-term strategic positioning. By increasing domestic production capacity, the company aims to reduce dependency on external supply chains while improving responsiveness to market demand. The initiative is also expected to enhance operational efficiency by reducing lead times between production stages.

In parallel, Novartis is expanding its US-based research and development footprint, signaling a more integrated approach between discovery, development, and manufacturing. This alignment is increasingly viewed as essential for accelerating innovation cycles, particularly in complex modalities, such as RNA-based therapeutics and radioligand therapies.

How does the new North Carolina facility fit into the broader network?

The Morrisville site builds on Novartis’ existing presence in North Carolina, complementing biologics manufacturing and sterile fill-finish operations already established in the region. Adding API production strengthens integration across the product lifecycle, enabling more efficient and flexible manufacturing workflows, according to a company press release.

The site is also designed to support multiple therapeutic modalities, including small molecules and RNA-based treatments, reflecting a shift toward platform-agnostic manufacturing systems. This flexibility is increasingly important as pipelines diversify and demand for specialized production grows.

What are the implications for the biopharma industry?

Novartis’ expansion highlights a broader industry shift toward regionalized, resilient manufacturing networks. The ability to produce medicines end-to-end within a single geography is becoming a competitive differentiator, particularly as companies navigate supply chain volatility.

The investment also signals continued momentum in advanced therapy manufacturing, including RNA-based and precision medicines that require specialized infrastructure. Over time, this approach may reduce production bottlenecks, accelerate time to market, and improve supply continuity for patients.

References

1. Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility. (2026 Apr 30). Globe Newswire. https://www.globenewswire.com/news-release/2026/04/30/3284676/0/en/novartis-finalizes-us-manufacturing-and-r-d-expansion-plan-with-seventh-new-facility.html
   
2. Novartis plans to expand its US-based manufacturing and R&D footprint with a total investment of $23B over the next 5 years. (2025 Apr 10). Novartis. https://www.novartis.com/us-en/news/media-releases/novartis-plans-expand-its-us-based-manufacturing-and-rd-footprint-total-investment-23b-over-next-5-years
   
3. Novartis Announces Plans to Build Flagship Manufacturing Hub in North Carolina. (2025 Nov 19). Novartis. Accessed April 30, 2026. https://www.novartis.com/us-en/news/media-releases/novartis-announces-plans-build-flagship-manufacturing-hub-north-carolina
   
4. Kansteiner, F. (2026 Feb 25). With Texas site, Novartis rounds out radiopharma production plans amid $23B US investment blitz. Fierce Pharma. https://www.fiercepharma.com/pharma/novartis-rounds-out-radiopharmaceutical-plans-amid-broader-23b-us-investment-blitz